Daxor Corporation (DXR) vs Harvard Bioscience, Inc. (HBIO)
- Daxor Corporation DXR 10.05 −1.47%
- Harvard Bioscience, Inc. HBIO 8.09 −2.65%
Daxor Corporation and Harvard Bioscience, Inc. are both Medical Instruments & Supplies companies. Daxor Corporation is the larger, with a market value of $59.6M against $37.8M — 1.6× the size. Harvard Bioscience, Inc. has negative trailing earnings, so its P/E is not meaningful; Daxor Corporation trades at 4.7×. Harvard Bioscience, Inc. grew revenue faster over the last twelve months: −1.06% against −52.1%. Harvard Bioscience, Inc. has the higher net margin (−11.9% vs −251.9%) and the lower return on invested capital (−0.41% vs 0.00%). Across the 17 metrics below, Daxor Corporation leads on 12 and Harvard Bioscience, Inc. on 5.
Valuation
Profitability
| Metric | DXR | HBIO | Medical Instruments & Supplies median |
|---|---|---|---|
| Gross margin | 0.00% | 58.16% | 54.29% |
| Operating margin | 0.00% | (0.28%) | 1.07% |
| Net margin | (251.91%) | (11.86%) | (1.61%) |
| Free cash flow margin | 224.51% | (2.09%) | 1.08% |
| Return on equity | 37.62% | (89.95%) | (1.32%) |
| Return on assets | 35.90% | (13.32%) | 0.00% |
| Return on invested capital | 0.00% | (0.41%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack